Sofia Ajeganova

researcher

Sofia Ajeganova is …
instance of (P31):
humanQ5

External links are
P856official websitehttps://cris.vub.be/en/persons/sofia-ajeganova(476a9c41-74e4-49a8-b941-d02716461ae4).html
P496ORCID iD0000-0001-9162-9717

P108employerVrije Universiteit BrusselQ612665
P735given name???Q18201520
???Q18201520
P106occupationresearcherQ1650915
P21sex or genderfemaleQ6581072

Reverse relations

author (P50)
Q90354326A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance
Q53040856A four-week team-rehabilitation programme in a warm climate decreases disability and improves health and body function for up to one year: A prospective study in Swedish patients with inflammatory joint diseases.
Q90603204Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al
Q61799672Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort
Q40117130Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts
Q95532931Association between dietary and metabolic factors and IgM antibodies to phosphorylcholine and malondialdehyde in patients with systemic lupus erythematosus and population-based matched controls
Q47885394Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset.
Q90447550Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus
Q35530495Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study.
Q84141759Carotid atherosclerosis, disease measures, oxidized low-density lipoproteins, and atheroprotective natural antibodies for cardiovascular disease in early rheumatoid arthritis -- an inception cohort study
Q53506587Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.
Q89210029Disease-modifying treatment in rheumatoid arthritis: treat early and do not forget to try to taper and stop
Q51074535Dr. Ajeganova and Dr. Hafström reply.
Q39677492Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis - a one year study.
Q86963759Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis
Q47364537IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors.
Q92013870Increased risk of osteoporotic fractures in Swedish patients with rheumatoid arthritis despite early treatment with potent disease-modifying anti-rheumatic drugs: a prospective general population-matched cohort study
Q51549596Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset--a prospective cohort study.
Q37704498Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial.
Q92670533Oxidative hotspots on actin promote skeletal muscle weakness in rheumatoid arthritis
Q40502497Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study.
Q51102106Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present.
Q28251716Rheumatoid arthritis: Seronegative and seropositive RA: alike but different?
Q89868356Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher pre
Q39139958Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.
Q58234648The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor
Q45106395The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis.
Q33750031The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical.
Q55405167Variation in pain related to systemic lupus erythematosus (SLE): a 7-year follow-up study.

Search more.